Dr. Carol A Tamminga, MD

Claim this profile

University of Texas Southwestern Medical Center

Studies Schizophrenia
Studies Bipolar disorder
3 reported clinical trials
5 drugs studied

Affiliated Hospitals

Image of trial facility.

University Of Texas Southwestern Medical Center

Clinical Trials Carol A Tamminga, MD is currently running

Image of trial facility.

Deep Brain Stimulation

for Schizophrenia

There are three hypotheses proposed for this study: 1) Participants will report no unanticipated serious adverse events during the eight months of treatment. 2) Investigators will successfully model psychotic versus non-psychotic brain states using support vector machine (SVM) classifiers. 3) Participants specific brain stimulation parameters can induce a change in the brain state consistent with non-psychotic states as measured by classifier output. Hypotheses 1, 2, and 3 address safety and tolerability, efficacy, and the putative mechanism of successful treatment. The overall objective is to use next generation Deep Brain Stimulation (DBS) combined with antecedent stereo electroencephalogram (SEEG) mapping to establish a new therapy for treatment-refractory schizophrenia given the limitations of current treatment modalities. The primary objective is to demonstrate safety of acute and chronic network guided stimulation for treatment-refractory schizophrenia. Exploratory Objectives: 1. Use intracranial mapping (SEEG) combined with pharmacological manipulation of psychotic states to create a protocol for participant specific deep brain stimulation to treat treatment-refractory schizophrenia. 2. Develop closed loop stimulation protocols to modify brain states during psychotic brain activity induced by low-dose ketamine administration. 3. Investigate the use of mnemonic similarity to characterize brain networks related to symptoms of treatment-refractory schizophrenia. 4. Treatment-related objectives: Record a reduction in psychotic symptoms, as well as an improvement in psychosocial function and cognition.

Recruiting

1 award

N/A

Image of trial facility.

Clozapine vs Risperidone

for Psychosis

The CLOZAPINE study is designed as a multisite study across 5 sites and is a clinical trial, involving human participants who are prospectively assigned to an intervention. The study will utilize a stringent randomized, double-blinded, parallel group clinical trial design. B2 group will serve as psychosis control with risperidone as medication control. The study is designed to evaluate effect of clozapine on the B1 participants, and the effect that will be evaluated is a biomedical outcome. The study sample will be comprised of individuals with psychosis, including 1) schizophrenia, 2) schizoaffective disorder and 3) psychotic bipolar I disorder. The investigators plan to initially screen and recruit n=524 (from both the existing B-SNIP library and newly-identified psychosis cases, \~50% each) in order to enroll n=320 (B1 and B2) into the RCT.

Recruiting

2 awards

Phase 4

7 criteria

More about Carol A Tamminga, MD

Clinical Trial Related

7 years of experience running clinical trials · Led 3 trials as a Principal Investigator · 2 Active Clinical Trials

Treatments Carol A Tamminga, MD has experience with

  • Clozapine
  • Risperidone
  • Deep Brain Stimulation
  • Electroconvulsive Therapy
  • Magnetic Seizure Therapy

Other Doctors you might be interested in

Frequently asked questions

Do I need insurance to participate in a trial?

What does Carol A Tamminga, MD specialize in?

Is Carol A Tamminga, MD currently recruiting for clinical trials?

Are there any treatments that Carol A Tamminga, MD has studied deeply?

What is the best way to schedule an appointment with Carol A Tamminga, MD?

What is the office address of Carol A Tamminga, MD?

Is there any support for travel costs?